Mechanisms of drug toxicity or intolerance

Digestive Diseases

Volumn 29, Issue 2, 2011, Pages 172-176

  Egan, Laurence J ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Drug interactions; Drug intolerance; Drug toxicity, classification; Polypharmacy

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AZATHIOPRINE; CYCLOSPORIN; CYTOCHROME P450; IBUPROFEN; ITRACONAZOLE; METHOTREXATE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PETHIDINE; PROTON PUMP INHIBITOR; SELEGILINE; WARFARIN;

ADVERSE DRUG REACTION; AUTOIMMUNE HEPATITIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; CROHN DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INTERACTION; DRUG METABOLISM; ENTERITIS; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GRAFT REJECTION; GRAPEFRUIT JUICE; HEART ATRIUM FIBRILLATION; HUMAN; LIVER GRAFT REJECTION; MYCOSIS; PARKINSON DISEASE; POLYPHARMACY; PRIORITY JOURNAL; STOMACH EROSION; STOMACH ULCER;

DRUG INTERACTIONS; DRUG TOLERANCE; DRUG TOXICITY; HUMANS;

EID: 79960120779     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000323881     Document Type: Conference Paper

References (14)

1. Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R, et al: ADE Prevention Study Group: Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 1995; 274: 29-34.
2. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205. (Pubitemid 28193431)
3. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P: Maintenance infliximab for Crohn's disease: the ACCENT I Randomised Trial. Lancet 2002; 359: 1541-1549. (Pubitemid 34621118)
4. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F, Schrenk UM, Dieterich DT: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-450. (Pubitemid 38988593)
5. Volpe M, Chin D, Paneni F: The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol 2010; 24: 9-17.
6. Jaruratanasirikul S, Sriwiriyajan S: Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54: 159-161. (Pubitemid 28204270)
7. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC: The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992; 42: 121-125.
8. Herlitz H, Edgar B, Hedner T, Lidman K, Karlberg I: Grapefruit juice: a possible source of variability in blood concentration of cyclosporin A. Nephrol Dial Transplant 1993; 8: 375. (Pubitemid 23129913)
9. Prager D, Rosman M, Bertino JR: Letter: azathioprine and allopurinol. Ann Intern Med 1974; 80: 427.
10. Jick H, Porter J: Drug-induced gastrointestinal bleeding. Report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Lancet 1978; 2: 87-89. (Pubitemid 8379631)
11. Zornberg GL, Bodkin JA, Cohen BM: Severe adverse interaction between pethidine and selegiline. Lancet 1991; 337: 246.
12. Wang L, Pelleymounter L, Weinshilboum R, Johnson JA, Hebert JM, Altman RB, Klein TE: Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenet Genomics 2010; 20: 401-405.
13. Egan LJ, Myhre GM, Mays DC, Dierkhising RA, Kammer PP, Murray JA: CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms Aliment Pharmacol Ther 2003; 17: 1521-1528. (Pubitemid 36831443)
14. Oyetayo OO, Talbert RL: Proton pump inhibitors and clopidogrel: is it a significant drug interaction? Expert Opin Drug Saf 2010; 9: 593-602.